Across the whole spectrum of ACS, clinical history data (such as older age, previous coronary events, and diabetes) and clinical variables (such as higher heart rate, lower blood pressure, and higher Killip class) are the most powerful prognostic determinants at multivariate analyses derived from large databases.
To our knowledge, this study demonstrates for the first time that high SSTR2 expression in HGG is associated with IDH1 mutation which is regarded as the most powerful prognostic marker for a favorable outcome compared to IDH1 wild-type gliomas [18].
Cytogenetic and molecular markers are currently the most powerful prognostic factors.
Despite its subjective nature, estimation of general condition by PS remains one of the most powerful prognostic factors in CUP patients [5] [6].
ERβ1 negativity appears to be the most powerful prognostic indicator of a reduced DFS, indicating that ERβ1 positive tumors are more likely to be responsive to TAM therapy.
In the total sample set, tumor stage was the most powerful prognostic variable with regard to three-year overall survival, (P<0.001).
Statin therapy at discharge was the most powerful prognostic indicator (HRs for total and cardiovascular mortality = 0.14, 95% CIs 0.06 to 0.33; P<0.001; and 0.20, 95% CIs 0.08 to 0.50; P = 0.001).
However, from our study, it is clear that ERβ1 negativity appears to be the most powerful prognostic factor influencing DFS in response to TAM treatment and this data is in agreement with previous observations showing that low level of ERβ predict resistance to TAM treatment [38].
Disease stage remains the most powerful prognostic factor for SCLC.
Among these parameters grading appears to constitute the most powerful prognostic histopathological feature.
